The median survival time has doubled!

On April 28, 2021, Galera Therapeutics announced that the investigational therapy GC4419 has achieved positive results in a phase 1/2 clinical trial for the treatment of patients with locally advanced pancreatic cancer.

Pancreatic cancer is known as the king of cancers and is one of the deadliest cancers.

Clinically, SBRT is increasingly used to treat locally advanced pancreatic cancer.

GC4419 is a highly selective and potent small molecule dismutase mimic, which can simulate the activity of human superoxide dismutase enzymes (SODs, superoxide dismutase enzymes), and quickly decompose superoxide free radicals into hydrogen peroxide.

▲The potential mechanism of GC4419 to improve the efficacy of radiotherapy (picture source: Galera Therapeutics official website)

Superoxide damages normal cells more than cancer cells, and hydrogen peroxide is more toxic to cancer cells than normal cells.

In the phase 1/2 clinical trial, 42 patients with locally advanced pancreatic cancer received at least 6 months of follow-up.

▲The latest results of GC4419 in Phase 1/2 clinical trials (picture source: reference [3])

Reference materials:

[1] Galera Announces Updated Data from its Randomized, Multicenter, Placebo-Controlled Trial in Patients with Pancreatic Cancer.

[2] https://#dismutase

[3] Galera Therapeutics Company Presentation.

Note: This article aims to introduce the progress of medical and health research, not to recommend treatment options.